The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Strategies for the management of adverse events associated with mTOR inhibitors
Open accessAbstract
Mammalian target of rapamycin (mTOR) inhibitors are used as potent immunosuppressive agents in solid-organ transplant recipients (everolimus and sirolimus) and as antineoplastic therapies for various cancers (eg, advanced renal cell carcinoma; everolimus, temsirolimus, ridaforolimus). Relevant literature, obtained from specific PubMed searches, was reviewed to evaluate the incidence and mechanistic features of specific adverse events (AEs) associated with mTOR inhibitor treatment, and to present strategies to effectively manage these events. The AEs examined in this review include stomatitis and other cutaneous AEs, wound-healing complications (eg, lymphocele, incisional hernia), diabetes/hyperglycemia, dyslipidemia, proteinuria, nephrotoxicity, delayed graft function, pneumonitis, anemia, hypertension, gonadal dysfunction, and ovarian toxicity. Strategies for selecting appropriate patients for mTOR inhibitor therapy and minimizing the risks of AEs are discussed, along with best practices for identifying and managing side effects. mTOR inhibitors are promising therapeutic options in immunosuppression and oncology; most AEs can be effectively detected and managed or reversed with careful monitoring and appropriate interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2010) · Cancer · doi:10.1002/cncr.25219 · Cited by 1,139
Kahan, B. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02480-6 · Cited by 913
MacDonald, A. S. (2001) · Transplantation · doi:10.1097/00007890-200101270-00019 · Cited by 621
Vincenti, F., Friman, S., Scheuermann, E., Rostaing, L., Jenssen, T., Campistol, J. M., Uchida, K., Pescovitz, M. D., Marchetti, P., Tuncer, M., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01749.x · Cited by 619
Houde, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A. (2010) · Diabetes · doi:10.2337/db09-1324 · Cited by 456
Fraenkel, M., Ketzinel-Gilad, M., Ariav, Y., Pappo, O., Karaca, M., Castel, J., Berthault, M.-F., Magnan, C., Cerasi, E., Kaiser, N., et al. (2008) · Diabetes · doi:10.2337/db07-0922 · Cited by 380
Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients
Johnston, O., Rose, C. L., Webster, A. C., & Gill, J. S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007111202 · Cited by 359
De Simone, P., Nevens, F., De Carlis, L., Metselaar, H. J., Beckebaum, S., Saliba, F., Jonas, S., Sudan, D., Fung, J., Fischer, L., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04212.x · Cited by 330
Kasiske, B., Cosio, F. G., Beto, J., Bolton, K., Chavers, B. M., Grimm, R., Levin, A., Masri, B., Parekh, R., Wanner, C., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6135.2004.0355.x · Cited by 316
SIROLIMUS-ASSOCIATED PULMONARY TOXICITY
Pham, P.-T. T., Pham, P.-C. T., Danovitch, G. M., Ross, D. J., Gritsch, H. A., Kendrick, E. A., Singer, J., Shah, T., & Wilkinson, A. H. (2004) · Transplantation · doi:10.1097/01.tp.0000118413.92211.b6 · Cited by 298
Silva Jr., H. T., Cibrik, D., Johnston, T., Lackova, E., Mange, K., Panis, C., Walker, R., Wang, Z., Zibari, G., & Kim, Y. S. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03129.x · Cited by 269
Vitko, S., Tedesco, H., Eris, J., Pascual, J., Whelchel, J., Magee, J. C., Campbell, S., Civati, G., Bourbigot, B., Filho, G. A., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00389.x · Cited by 254
Busaidy, N. L., Farooki, A., Dowlati, A., Perentesis, J. P., Dancey, J. E., Doyle, L. A., Brell, J. M., & Siu, L. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7356 · Cited by 231
Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1
Mah??, E., Morelon, E., Lechaton, S., Sang, K.-H. L. Q., Mansouri, R., Ducasse, M.-F., Mamzer-Bruneel, M.-F., de Prost, Y., Kreis, H., & Bodemer, C. (2005) · Transplantation · doi:10.1097/01.tp.0000151630.25127.3a · Cited by 228
Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
White, D. A., Camus, P., Endo, M., Escudier, B., Calvo, E., Akaza, H., Uemura, H., Kpamegan, E., Kay, A., Robson, M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200911-1720oc · Cited by 210
Patient Survival and Cardiovascular Risk After Kidney Transplantation: The Challenge of Diabetes
Cosio, F. G., Hickson, L. J., Griffin, M. D., Stegall, M. D., & Kudva, Y. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.02101.x · Cited by 204
Accelerated wound healing by mTOR activation in genetically defined mouse models
Squarize, C. H., Castilho, R. M., Bugge, T. H., & Gutkind, J. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010643 · Cited by 203
Adverse events associated with mTOR inhibitors
Pallet, N., & Legendre, C. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752814 · Cited by 198
Inhibition of MTOR Disrupts Autophagic Flux in Podocytes
Cinà, D. P., Onay, T., Paltoo, A., Li, C., Maezawa, Y., De Arteaga, J., Jurisicova, A., & Quaggin, S. E. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011070690 · Cited by 172
Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation
McTaggart, R. A., Gottlieb, D., Brooks, J., Bacchetti, P., Roberts, J. P., Tomlanovich, S., & Feng, S. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00078.x · Cited by 170
Nashan, B., & Citterio, F. (2012) · Transplantation · doi:10.1097/tp.0b013e3182551021 · Cited by 166
Hypertension After Kidney Transplant
Mangray, M., & Vella, J. P. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.10.048 · Cited by 165
Hong, J. C., & Kahan, B. D. (2000) · Transplantation · doi:10.1097/00007890-200005270-00019 · Cited by 162
Sonis, S., Treister, N., Chawla, S., Demetri, G., & Haluska, F. (2010) · Cancer · doi:10.1002/cncr.24696 · Cited by 161
Huyghe, E., Zairi, A., Nohra, J., Kamar, N., Plante, P., & Rostaing, L. (2007) · Transplant International · doi:10.1111/j.1432-2277.2006.00423.x · Cited by 159
Porta, C., Osanto, S., Ravaud, A., Climent, M. Á., Vaishampayan, U. N., White, D. A., Creel, P. A., Dickow, B., Fischer, P., Gornell, S., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.02.014 · Cited by 154
A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients
Martins, F., de Oliveira, M. A., Wang, Q., Sonis, S. T., Gallottini, M. H. C., George, S., & Treister, N. S. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2012.11.008 · Cited by 142
mToR inhibitors-induced proteinuria: mechanisms, significance, and management
Letavernier, E., & Legendre, C. M. (2008) · Transplantation Reviews · doi:10.1016/j.trre.2007.12.001 · Cited by 141
SYNERGISTIC EFFECTS OF CYCLOSPORINE AND RAPAMYCIN IN A CHRONIC NEPHROTOXICITY MODEL1
Andoh, T. F., Lindsley, J. N., Franceschini, N., et al. (1996) · Transplantation · doi:10.1097/00007890-199608150-00002 · Cited by 131
Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil
van Gelder, T., ter Meulen, C. G., Hen, R. J., et al. (2003) · Transplantation · doi:10.1097/01.tp.0000056639.74982.f9 · Cited by 131
Clinical presentation and management of mTOR inhibitor-associated stomatitis
de Oliveira, M. A., Martins, F., Wang, Q., Sonis, S. T., Demetri, G. D., George, S., Butrynski, J. E., & Treister, N. S. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.08.009 · Cited by 131
Management of Side Effects of Sirolimus Therapy
Stallone, G., Infante, B., Grandaliano, G., & Gesualdo, L. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a05b7a · Cited by 131
Langer, R. M., Hené, R. J., Vitko, S., Christiaans, M. H. L., Junior, H. T. S., Ciechanowski, K., Cassuto, É., Rostaing, L. P. E., Vilatobá, M., Machein, U., et al. (2012) · Transplant International · doi:10.1111/j.1432-2277.2012.01465.x · Cited by 131
The podocyte as a direct target of immunosuppressive agents
Schönenberger, E., Ehrich, J. H. H., Haller, H. G., & Schiffer, M. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq617 · Cited by 129
Risk factors for impaired wound healing in sirolimus‐treated renal transplant recipients
Knight, R. J., Villa, M. A., Laskey, R., Benavides, C. A., Schoenberg, L., Welsh, M. S., Kerman, R. H., Podder, H., Buren, C. T. V., Katz, S. M., et al. (2007) · Clinical Transplantation · doi:10.1111/j.1399-0012.2007.00668.x · Cited by 115
Targeting mTOR Pathways in Human Malignancies
Fasolo, A., & Sessa, C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800626210 · Cited by 112
Proteinuria in Kidney Transplant Recipients: Prevalence, Prognosis, and Evidence-Based Management
Knoll, G. A. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.06.031 · Cited by 110
Defects in Skin γδ T Cell Function Contribute to Delayed Wound Repair in Rapamycin-Treated Mice
Mills, R. E., Taylor, K. R., Podshivalova, K., McKay, D. B., & Jameson, J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3974 · Cited by 98
Bacterial clearance of biologic grafts used in hernia repair: an experimental study
Harth, K. C., Broome, A., Jacobs, M. R., Blatnik, J. A., Zeinali, F., Bajaksouzian, S., & Rosen, M. J. (2011) · Surgical Endoscopy · doi:10.1007/s00464-010-1534-8 · Cited by 92
Sirolimus Impairs Gonadal Function in Heart Transplant Recipients
Kaczmarek, I., Groetzner, J., Adamidis, I., Landwehr, P., Mueller, M., Vogeser, M., Gerstorfer, M., Überfuhr, P., Meiser, B., & Reichart, B. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00456.x · Cited by 91
mTOR inhibitor‐associated dermatologic and mucosal problems
Campistol, J. M., de Fijter, J. W., Flechner, S. M., et al. (2010) · Clinical Transplantation · doi:10.1111/j.1399-0012.2010.01232.x · Cited by 91
Duerr, M., Glander, P., Diekmann, F., Dragun, D., Neumayer, H.-H., & Budde, K. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07371009 · Cited by 91
Testosterone Concentrations and Sirolimus in Male Renal Transplant Patients
Fritsche, L., Budde, K., Dragun, D., Einecke, G., Diekmann, F., & Neumayer, H. (2003) · American Journal of Transplantation · doi:10.1046/j.1600-6135.2003.00279.x · Cited by 89
The metabolic effects of cyclosporin and tacrolimus
Marchetti, P., & Navalesi, R. (2000) · Journal of Endocrinological Investigation · doi:10.1007/bf03343761 · Cited by 88
mTOR inhibitor–associated proteinuria in kidney transplant recipients
Diekmann, F., Andrés, A., & Oppenheimer, F. (2011) · Transplantation Reviews · doi:10.1016/j.trre.2011.10.003 · Cited by 79
Tenderich, G., Fuchs, U., Zittermann, A., Muckelbauer, R., Berthold, H. K., & Köerfer, R. (2007) · Clinical Transplantation · doi:10.1111/j.1399-0012.2007.00686.x · Cited by 78
Dantal, J., Berthoux, F. C., Moal, M., et al. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01094.x · Cited by 72
Managing Stomatitis in Patients Treated With Mammalian Target of Rapamycin Inhibitors
Pilotte, A. P., Hohos, M., Polson, K., Huftalen, T. M., & Treister, N. S. (2011) · Clinical journal of oncology nursing · doi:10.1188/11.cjon.e83-e89 · Cited by 72
Stallone, G., Infante, B., Pontrelli, P., Gigante, M., Montemurno, E., Loverre, A., Rossini, M., Schena, F. P., Grandaliano, G., & Gesualdo, L. (2011) · Transplantation · doi:10.1097/tp.0b013e318211d342 · Cited by 67
Mahé, E., Morélon, E., Lechaton, S., Drappier, J.-C., Prost, Y. D., Kreis, H., & Bodemer, C. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.11.1072 · Cited by 64
Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation
Jacobson, P. A., Schladt, D., Oetting, W. S., Leduc, R. E., Guan, W., Matas, A. J., Lamba, V., Mannon, R. B., Julian, B. A., & Israni, A. K. (2010) · Transplantation · doi:10.1097/tp.0b013e318200e971 · Cited by 63
Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications
Lieberthal, W., & Levine, J. S. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00015.2012 · Cited by 61
Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism
Desai, N., Heenan, S. D., & Mortimer, P. S. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09098.x · Cited by 60
Christians, U., Gottschalk, S., Miljus, J., Hainz, C., Benet, L. Z., Leibfritz, D., & Serkova, N. J. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705939 · Cited by 60
Sirolimus-Associated Testicular Toxicity
Rovira, J., Diekmann, F., Ramírez-Bajo, M. J., et al. (2012) · Transplantation · doi:10.1097/tp.0b013e31824bf1f0 · Cited by 58
Rodríguez-Pascual, J., Cheng, E. Y. L., Maroto, P., & Durán, I. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833760bf · Cited by 55
Human acellular dermal matrix for ventral hernia repair reduces morbidity in transplant patients
Brewer, M. B., Rada, E. M., Milburn, M. L., Goldberg, N. H., Singh, D. P., COOPER, M. M., & Silverman, R. (2010) · Hernia · doi:10.1007/s10029-010-0748-y · Cited by 54
Surgical wound complications after heart transplantation
Zuckermann, A. O., & Barten, M. J. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01247.x · Cited by 53
Sánchez-Fructuoso, A. I., Ruiz, J. C., Pérez-Flores, I., Alamillo, C. G., Romero, N. C., & Arias, M. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.07.083 · Cited by 53
Alterations of the Female Reproductive System in Recipients of Islet Grafts
Cure, P., Pileggi, A., Froud, T., Norris, P. M., Baidal, D. A., Cornejo, A., Hafiz, M. M., Ponte, G., Poggioli, R., Yu, J. H., et al. (2004) · Transplantation · doi:10.1097/01.tp.0000147301.41864.c0 · Cited by 50
Anaemia, microcytosis and sirolimus--is iron the missing link?
Sofroniadou, S., Kassimatis, T. I., & Goldsmith, D. J. A. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp674 · Cited by 48
Krämer, B. K., Neumayer, H. H., Stahl, R. K., et al. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.09.026 · Cited by 46
Wiseman, A. C., McCague, K., Kim, Y., Geißler, F., & COOPER, M. M. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04334.x · Cited by 45
Braun, M., Young, J., Reiner, C. S., Poster, D., Krauer, F., Kistler, A. D., Kristanto, P., Wang, X., Liu, Y., Loffing, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045868 · Cited by 43
Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation
Campistol, J. M., Cockwell, P., Diekmann, F., Donati, D., Guirado, L., Herlenius, G., Mousa, D. H., Pratschke, J., & Ruiz, J. C. (2009) · Transplant International · doi:10.1111/j.1432-2277.2009.00858.x · Cited by 40
Zeier, M. G., & van der Giet, M. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01140.x · Cited by 38
Alfadhli, E. M., Koh, A., Albaker, W. I., Bhargava, R., Ackerman, T. E., McDonald, C. G., Ryan, E. A., Shapiro, A. M. J., & Senior, P. A. (2009) · Transplant International · doi:10.1111/j.1432-2277.2009.00839.x · Cited by 37
Posttransplant anemia: the role of sirolimus
Fishbane, S., Cohen, D. J., Coyne, D. W., Djamali, A., Singh, A. K., & Wish, J. B. (2009) · Kidney International · doi:10.1038/ki.2009.231 · Cited by 34
mTOR inhibition and erythropoiesis: microcytosis or anaemia?
Diekmann, F., Rovira, J., Díaz‐Ricart, M., Arellano, E. M., Vodenik, B., Jou, J. M., Corrons, J. V., Escolar, G., & Campistol, J. M. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr318 · Cited by 34
Clinical recommendations for the use of everolimus in heart transplantation
Manito, N., Delgado, J. F., Crespo-Leiro, M. G., González-Vílchez, F., Almenar, L., Arizón, J. M., Díaz, B., Fernàndez-Yáñez, J., Mirabet, S., Palomo, J., et al. (2010) · Transplantation Reviews · doi:10.1016/j.trre.2010.01.005 · Cited by 32
Sánchez-Fructuoso, A. I., Calvo, N., Moreno, M. A., Giorgi, M., & Barrientos, A. (2007) · Transplantation Proceedings · doi:10.1016/j.transproceed.2007.06.032 · Cited by 30
Kirsch, A. H., Riegelbauer, V., Tagwerker, A., Rudnicki, M., Rosenkranz, A. R., & Eller, K. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00180.2012 · Cited by 26
Causes and consequences of proteinuria following kidney transplantation.
Fernández, M., & G-Cosío, F. (2011) · PubMed · doi:10.3265/nefrologia.pre2011.may.10972 · Cited by 25
Alasker, A., Meskawi, M., Sun, M., Ismail, S., Hanna, N., Hansen, J., Tian, Z., Bianchi, M., Perrotte, P., & Karakiewicz, P. I. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.006 · Cited by 23
A drug safety evaluation of everolimus in kidney transplantation
Holdaas, H., Midtvedt, K., & Åsberg, A. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.722993 · Cited by 22
Gerullis, H., Bergmann, L., Maute, L., Eimer, C., & Otto, T. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0835-2 · Cited by 20
McDonald, M. A., Gustafsson, F., Almasood, A. S., Barth, D. S., & Ross, H. J. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.05.158 · Cited by 12
Cited by
Henske, E. P., Jóźwiak, S., Kingswood, J. C., Sampson, J. R., & Thiele, E. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.35 · Cited by 831
Northrup, H., Aronow, M. E., Bebin, E. M., Bissler, J., Darling, T. N., de Vries, P. J., Frost, M. D., Fuchs, Z., Gosnell, E. S., Gupta, N., et al. (2021) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2021.07.011 · Cited by 736
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
LoRusso, P. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0018 · Cited by 470
Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Decourt, B., Lahiri, D. K., & Sabbagh, M. N. (2017) · Current Alzheimer Research · doi:10.2174/1567205013666160930110551 · Cited by 371
Poised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301
Metadata
- Authors
- Kaplan, B., Qazi, Y., & Wellen, J. R.
- Venue
- Transplantation Reviews
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 28
- Issue
- 3
- Pages
- 126-133
- ISSN
- 0955-470X (ISSN-L)
- OpenAlex
- W2002870649
- Cited by
- 322
- References
- 80
- FWCI
- 28.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.